NCI Drug Dictionary

The NCI Drug Dictionary contains technical definitions and synonyms for drugs/agents used to treat patients with cancer or conditions related to cancer. Each drug entry includes links to check for clinical trials listed in NCI's List of Cancer Clinical Trials.

CD40L-Fc fusion protein MEDI 5083
A fusion protein composed of CD40 ligand (CD40L; CD154; TRAP; TNFSF5) fused to a modified immunoglobulin (Ig) Fc fragment, with potential immunostimulating activity. Upon administration of the CD40L-Fc fusion protein MEDI5083, the CD40L moiety specifically targets and binds to and activates CD40, a cell surface receptor that belongs to the tumor necrosis factor (TNF) receptor family and is expressed on various immune cells, such as B lymphocytes, monocytes, and dendritic cells (DCs). Activation of CD40 induces proliferation and activation of B lymphocytes, shifts the induction of suppressive macrophages towards immunostimulatory macrophages, activates monocyte-derived DCs (moDCs), and leads to the secretion of inflammatory cytokines, which activates the immune system to induce the proliferation and activation of cytotoxic T lymphocytes (CTLs) against tumor cells. Altogether, this may cause tumor cell lysis. Check for active clinical trials using this agent. (NCI Thesaurus)

Code name:MEDI 5083